Clinical trials: Age Related Maculopathy
Geographic Atrophy
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic…
- Trial name
- NCT02515942
- Testing
- CLG561, LFG316
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
- Trial name
- VAULT (NCT01950741)
- Testing
- aflibercept
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Pusan National University Hospital
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Background: Wet age-related macular degeneration (AMD) occurs when abnormal blood vessels grow in the back of the eye, and leak blood and other fluids that damage the eye, produce scarring, and lead to blindness.
- Trial name
- NCT01271270
- Testing
- Palomid 529
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Age Related Macular Degeneration (AMD)
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
- Trial name
- ORACLE (NCT05481827)
- Testing
- GT005
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 225 people
- Sponsor
- Gyroscope Therapeutics Limited
Dry Age-related Macular Degeneration, Geographic Atrophy
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration
- Trial name
- i-GAIN (NCT05797896)
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 234 people
- Sponsor
- Complement Therapeutics
Age Related Macular Degeneration
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
This is a single-masked study to compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal…
- Trial name
- LAST (NCT01115556)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age Related Macular Degeneration
Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies.
- Trial name
- TARMAC-1 (NCT03630562)
- Testing
- Aqueous humor samples collection
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Age-Related Macular Degeneration, Retinal Function
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
Multifocal-electroretinoram (ERG) and microperimetry are objective criteria to asses retinal function. No information besides visual acuity exist for the development of retinal function during the course of wet AMD during therapy…
- Trial name
- LucERG (NCT01269151)
- Testing
- Lucentis (Ranibizumab)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Luebeck
Age-Related Macular Degeneration
Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal
To assess the five-year incidence of AMD in a population from the central region of Portugal, previously phenotypically characterized.
- Trial name
- AMDIncidencePT (NCT02748824)
- Where
- Portugal
- Volunteers
- 5,996 people, healthy volunteers welcome
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Neovascular Age-related Macular Degeneration
Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
The main objective is to determine the efficacy of intravitreal administration of Ranibizumab combined with intravitreous injection of expansile gas and induction of posterior vitreous detachment on best-corrected visual acuity…
- Trial name
- NCT01291121
- Testing
- Intravitreal expansile gas and ranibizumab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Geographic Atrophy, Age-Related Macular Degeneration
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Trial name
- K8 for GA (NCT06164587)
- Testing
- K8
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Inflammasome Therapeutics
Neovascular Age-related Macular Degeneration
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question[s] it aims to answer are: Safety of the maximum tolerable dose of AXT107 Bioactivity and…
- Trial name
- DISCOVER (NCT05859776)
- Testing
- AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- AsclepiX Therapeutics, Inc.
Age-related Macular Degeneration (AMD)
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration…
- Trial name
- LADIGAGA (NCT04292080)
- Testing
- Dimethyl Fumarate (TECFIDERA™), No active : no treatment
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Age-Related Macular Degeneration
Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity
Although the number of wet AMD patients with the better visual acuity is increasing, the visual improvement in patients with the better vision may not be so significant after anti-vascular endothelial growth factor (VEGF)…
- Trial name
- NCT06330220
- Testing
- Aflibercept Injection [Eylea]
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Subfoveal Choroidal Neovascularization (CNV), Secondary to Age-related Macular Degeneration (AMD)
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular…
- Trial name
- NCT00504959
- Testing
- ranibizumab
- Where
- 36 sites in Australia, Belgium and 8 more
- Volunteers
- 234 people
- Sponsor
- Novartis
Maculopathy, Age-Related, Choroidal Neovascularization
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
The purpose of this study is to determine the sensitivity of the optical coherence tomography (OCT) test in detecting neovascular AMD in eyes at high risk for CNV development.
- Trial name
- NCT00417846
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Johns Hopkins University
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.